Maze Therapeutics, Inc. (MAZE) stock
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$32.43+1.23 (+3.94%)
Close on Nov 19, 2026Market cap $1.80BP/E –Yield –
Maze Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Maze Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$106.84M. For fiscal 2025 it was -$112.73M, down 250.7% from the year before.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$112.73M | -250.7% |
| FY2024 | Dec 31, 2024 | $74.81M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$39.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$27.76M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.71M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.45M | -121.0% |
| Q1 FY2025 | Mar 31, 2025 | -$29.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.31M | – |
| Q2 FY2024 | Jun 30, 2024 | $144.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.72M | – |
See a number that looks wrong?